Legacy Capital Wealth Partners LLC Sells 13,895 Shares of Kenvue Inc. (NYSE:KVUE)

Legacy Capital Wealth Partners LLC reduced its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 30.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,231 shares of the company's stock after selling 13,895 shares during the quarter. Legacy Capital Wealth Partners LLC's holdings in Kenvue were worth $773,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Pittenger & Anderson Inc. acquired a new position in Kenvue during the 1st quarter worth $30,000. TruNorth Capital Management LLC acquired a new position in Kenvue during the 1st quarter worth $36,000. Continuum Advisory LLC lifted its holdings in Kenvue by 2,071.1% during the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock worth $47,000 after buying an additional 1,864 shares in the last quarter. Clarity Asset Management Inc. acquired a new position in Kenvue during the 4th quarter worth $45,000. Finally, Rossby Financial LCC acquired a new position in Kenvue during the 1st quarter worth $52,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of NYSE KVUE traded up $0.03 during midday trading on Thursday, reaching $21.88. The company's stock had a trading volume of 12,994,683 shares, compared to its average volume of 17,448,924. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86. Kenvue Inc. has a fifty-two week low of $17.85 and a fifty-two week high of $25.17. The business's 50 day moving average price is $22.24 and its two-hundred day moving average price is $22.29. The company has a market cap of $41.97 billion, a P/E ratio of 39.77, a P/E/G ratio of 3.33 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same period in the previous year, the business earned $0.28 earnings per share. The firm's quarterly revenue was down 3.9% on a year-over-year basis. On average, analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on KVUE. Redburn Atlantic began coverage on Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target on the stock. Bank of America cut their price target on Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a research note on Tuesday. Evercore ISI initiated coverage on Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target on the stock. UBS Group dropped their price objective on Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research note on Thursday. Finally, Barclays dropped their price objective on Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Tuesday. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Kenvue currently has an average rating of "Hold" and a consensus price target of $24.71.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.